AT
Avrion Therapeutics develops precision gene therapies targeting neurodegenerative diseases by utilizing advanced gene editing techniques to modify genetic material. The company aims to address the underlying genetic causes of conditions such as Alzheimer's and Parkinson's, offering potential for disease modification and improved patient outcomes.
Updated 4 months ago
Funding
$3.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- Avrion Therapeutics develops precision gene therapies targeting neurodegenerative diseases by utilizing advanced gene editing techniques to modify genetic material. The company aims to address the underlying genetic causes of conditions such as Alzheimer's and Parkinson's, offering potential for disease modification and improved patient outcomes.